Investor Relations

Corporate Profile

PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products. The PLxGuard™  drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx Pharma believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

Stock Quote

Exchange
Volume
Today's Open
Previous Close

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart

Recent News

Date Title
05/03/21
Summary TogglePLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business Update
SPARTA, N.J. , May 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products, with its lead
03/12/21
Summary TogglePLx Pharma Inc. Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
-- Received FDA approval of sNDAs for both VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsule -- -- U.S. commercial launch of VAZALORE planned for third quarter 2021 -- -- Secured $63 million of gross proceeds in an underwritten public offering of common stock for the
03/11/21
Summary TogglePLx Pharma Inc. to Present at the Oppenheimer 31st Annual Healthcare Conference
SPARTA, N.J. , March 11, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead

Upcoming Events

References: 1. Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin–phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272-277. 2. Bhatt DL, Grosser T, Dong JF, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. JACC. 2017;69(6):603-612.